A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis"

被引：0
|
作者：
Ismaila, Afisi S. [1 ,2 ]
Haeussler, Katrin [3 ]
Malmenas, Mia [4 ]
Sharma, Raj [5 ]
Compton, Chris [5 ]
Vogelmeier, Claus F. [6 ,7 ]
Han, MeiLan K. [8 ]
Halpin, David M. G. [9 ]
机构：
[1] GSK, Value Evidence & Outcomes, 1250 South Collegeville Rd, Collegeville, PA 19426 USA
[2] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[3] ICON Plc, ICON Hlth Econ, Munich, Germany
[4] ICON Plc, ICON Hlth Econ, Stockholm, Sweden
[5] GSK, Value Evidence & Outcomes, R&D Global Med, Brentford, England
[6] Philipps Univ Marburg, German Ctr Lung Res DZL, Dept Med Pulm & Crit Care Med, Marburg, Germany
[7] German Ctr Lung Res DZL, Marburg, Germany
[8] Univ Michigan, Div Pulm & Crit Care, Ann Arbor, MI USA
[9] Univ Exeter, Med Sch, Coll Med & Hlth, Exeter, England
来源：
ADVANCES IN THERAPY | 2023年 / 40卷 / 05期
关键词：
COPD; Fixed-effects model; Fluticasone furoate/umeclidinium/vilanterol; Heterogeneity; Indirect treatment comparison; Network meta-analysis; Random effects model; Triple therapy; OBSTRUCTIVE PULMONARY-DISEASE; EFFICACY;
D O I：
10.1007/s12325-023-02495-0
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：2556 / 2561
页数：6
相关论文
共 50 条
  • [31] Population pharmacokinetic (PK) analysis of fluticasone furoate (FF)/umeclidimium (UMEC)/vilanterol (VI) via a single inhaler in patients with COPD (FULFIL)
    Mehta, Rashmi
    Pefani, Eleni
    Beerahee, Misba
    Barnacle, Helen
    Birk, Ruby
    Brealey, Noushin
    Zhu, Chang-Qing
    Lipson, David A.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [32] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Ismaila, Afisi S.
    Rothnie, Kieran J.
    Wood, Robert P.
    Banks, Victoria L.
    Camidge, Lucinda J.
    Czira, Alexandrosz
    Compton, Chris
    Sharma, Raj
    Millard, Shannon N.
    Massey, Olivia
    Halpin, David M. G.
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [33] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Afisi S. Ismaila
    Kieran J. Rothnie
    Robert P. Wood
    Victoria L. Banks
    Lucinda J. Camidge
    Alexandrosz Czira
    Chris Compton
    Raj Sharma
    Shannon N. Millard
    Olivia Massey
    David M. G. Halpin
    Respiratory Research, 24
  • [34] SINGLE-INHALER TRIPLE THERAPY FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL COMPARED WITH TIOTROPIUM MONOTHERAPY IN COPD: A POST HOC ANALYSIS BY AIRFLOW LIMITATION
    Anzueto, Antonio
    Obeid, Dany
    Bansal, Sandeep
    Brown, Nicola
    Compton, Christopher
    Corbridge, Thomas
    Dorais, Kelly
    Erb, David
    Harvey, Catherine
    Kaisermann, Morrys
    Kaye, Mitchell
    Lipson, David
    Martin, Neil
    Zhu, Chang-Qing
    Papi, Alberto
    CHEST, 2020, 158 (04) : 1705A - 1707A
  • [35] Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Afisi S. Ismaila
    Kieran J. Rothnie
    Robert P. Wood
    Victoria L. Banks
    Lucinda J. Camidge
    Alexandrosz Czira
    Chris Compton
    Raj Sharma
    Shannon N. Millard
    Olivia Massey
    David M. G. Halpin
    Respiratory Research, 25
  • [36] A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD
    Rodrigo, Gustavo J.
    Neffen, Hugo
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2017, 42 : 1 - 6
  • [37] Effect of fluticasone furoate (FF)/vilanterol (VI) compared with VI on acute exacerbations of COPD (AECOPD): A post-hoc analysis by baseline airflow obstruction
    Leather, David
    Yates, Louisa
    Newlands, Amy
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [38] Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis
    Huisman, Eline
    Sion, Katya
    Punekar, Yogesh
    Karabis, Andreas
    Naya, Ian
    Ismaila, Afisi
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [39] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study (vol 24, 229, 2023)
    Ismaila, Afisi S.
    Rothnie, Kieran J.
    Wood, Robert P.
    Banks, Victoria L.
    Camidge, Lucinda J.
    Czira, Alexandrosz
    Compton, Chris
    Sharma, Raj
    Millard, Shannon N.
    Massey, Olivia
    Halpin, David M. G.
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [40] Preventing Clinically Important Deterioration (CID) of COPD with Single-inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol: A Prospective Analysis of the IMPACT Trial
    Han, M. K.
    Criner, G. J.
    Dransfield, M. T.
    Halpin, D. M. G.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lipson, D. A.
    Lomas, D. A.
    Martinez, F. J.
    Naya, I.
    Pascoe, S. J.
    Wise, R. A.
    Singh, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345